Single User License:
EpCAM Antagonists Market - Global
Industry Analysis, Size, Share,
Growth, Trends And Forecast 2015 2023
USD 4315.5
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
www.transparencymarketresearch.com
sales@transparencymarketresearch.com
Flat 10% Discount!!
Free Customization as per your requirement
You will get Custom Report at Syndicated Report
price
Report will be delivered with in 15-20 working days
Request Sample
Buy Now
REPORT DESCRIPTION
EpCAM stands for epithelial cell adhesion molecule which is a cell surface protein (antigen) and is highly expressed
in major cancer types such as breast, prostate, colon, ovarian, gastric, lung and pancreatic cancer. It is thus
considered as a well established marker for cancer of epithelial origin and an ideal therapeutic target. It is not only
limited to epithelial carcinomas but can also be expressed in various other epithelial tissues, progenitor and stem
cells. EpCAM is not found in non-epithelial cells or in cancer without epithelial origin. EpCAM plays significant role
during cell adhesion, proliferation, cell signaling, migration and differentiation. Over expression of EpCAM has been
shown to promote the proliferation in primary breast carcinomas (PBCs) and other cancer types.
Browse Full Report with TOC @ http://www.transparencymarketresearch.com/epcam-antagonists-market.html
EpCAM is usually expressed in embryonic epithelia in human and mouse; however the levels typically go down as
cells attain terminal differentiation. Catumaxomab and edrecolomab are major antibodies which are designed to bind
with epithelial cell adhesion molecules. Catumaxomab, a hybrid monoclonal antibody of rat-mouse is marketed
under the brand name Removab. Catumaxomab, developed by Fresenius Biotech and Trion Pharma GmbH, is used to
treat malignant ascites in patient with metastasizing tumor by binding...